Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

The decision to advance prasinezumab to Phase III was based on results from the Phase IIb PADOVA trial, which demonstrated ...

Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.

Roche and AbbVie have come up short again in their effort to gain an additional indication for their blockbuster blood cancer ...